Inhibition of phosphodiesterase‐3 by levosimendan is sufficient to account for its inotropic effect in failing human heart
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Levosimendan is known as a calcium sensitizer, although it is also known to inhibit PDE 3. We aimed to isolate each component and estimate their contribution to the increased cardiac contractility induced by levosimendan. Experimental Approach: Contractile force was measured in electrically stimulated ventricular strips from explanted failing human hearts and left ventricular strips from normal male Wistar rats.PDE activity was measured in a two‐step PDE activity assay on failing human ventricle. Key Results: Levosimendan exerted a positive inotropic effect (PIE) reaching maximum at 10−5 M in ventricular strips from failing human hearts. In the presence of the selective PDE3 inhibitor cilostamide, the PIE of levosimendan was abolished. During treatment with a PDE4 inhibitor and a supra‐threshold concentration of isoprenaline, levosimendan generated an amplified inotropic response. This effect was reversed by β‐adrenoceptor blockade and undetectable in strips pretreated with cilostamide. Levosimendan (10−6 M) increased the potency of β‐adrenoceptor agonists by 0.5 log units in failing human myocardium, but not in the presence of cilostamide. Every inotropic response to levosimendan was associated with a lusitropic response. Levosimendan did not affect the concentration–response curve to calcium in rat ventricular strips, in contrast to the effects of a known calcium sensitizer,EMD 57033 [5‐(1‐(3,4‐dimethoxybenzoyl)‐1,2,3,4‐tetrahydroquinolin‐6‐yl)‐6‐methyl‐3,6‐dihydro‐2H‐1,3,4‐thiadiazin‐2‐one].PDE activity assays confirmed that levosimendan inhibited PDE3 as effectively as cilostamide. Conclusions and Implications: Our results indicate that the PDE3‐inhibitory property of levosimendan was enough to account for its inotropic effect, leaving a minor, if any, effect to a calcium‐sensitizing component.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Cited by
Chioncel, O., Parissis, J., Mebazaa, A., Thiele, H., Desch, S., Bauersachs, J., Harjola, V.-P., Antohi, E.-L., Arrigo, M., Ben Gal, T., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1922 · Cited by 493
Atherton, J. J., Sindone, A., De Pasquale, C. G., Driscoll, A., MacDonald, P. S., Hopper, I., Kistler, P. M., Briffa, T., Wong, J., Abhayaratna, W., et al. (2018) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2018.06.1042 · Cited by 431
Targeting the sarcomere to correct muscle function
Hwang, P. M., & Sykes, B. D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4554 · Cited by 114
Keung, W., Chan, P. K. W., Backeris, P. C., Lee, E. K., Wong, N., Wong, A. O. T., Wong, G. K. Y., Chan, C. W. Y., Fermini, B., Costa, K. D., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1385 · Cited by 54
Seilitz, J., Grafver, I., Kiszakiewicz, L., Oikonomakis, I., Jansson, K., Axelsson, B., & Nilsson, K. F. (2021) · Shock · doi:10.1097/shk.0000000000001726 · Cited by 10
“Levosimendan is believed to be a calcium sensitizer, but it has been suggested that the main mechanism is phosphodiesterase III inhibition (27, 28).”
Background
Metadata
- Authors
- Ørstavik, Ø., Ata, S. H., Riise, J., Dahl, C. P., Andersen, G. Ø., Levy, F. O., Skomedal, T., Osnes, J., & Qvigstad, E.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-11-24
- Volume
- 171
- Issue
- 23
- Pages
- 5169-5181
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1822797420
- Cited by
- 74
- References
- 3
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.